title: Prognostic significance of the mRNA expression ofERCC1,RRM1,TUBB3andTYMSgenes in patients with non-small cell lung cancer.
abstract: The present study aimed to investigate the prognostic value of excision repair cross-complementing 1 (ERCC1), ribonucleotide reductase subunit M1 (RRM1), class III β-tubulin (TUBB3) and thymidylate synthase (TYMS) in patients with non-small cell lung cancer (NSCLC) receiving platinum-based adjuvant chemotherapy. The mRNA expression of these genes was assessed in 72 tumor tissue samples obtained following surgery, using multiplex branched-DNA technology. Subsequent to surgery, all 72 patients with NSCLC were treated with platinum-based chemotherapy. The expression of these five genes was analyzed and the correlation with clinical characteristics and patient survival was investigated. Among the 72 samples, the incidence rate of mRNA expression ofERCC1was 38.9% (28/72),RRM1was 55.6% (40/72),TUBB3was 47.2% (34/72) andTYMSwas 62.5% (45/72). The incidence rate ofERCC1expression in adenocarcinoma (34.2%) was significantly lower than that in non-adenocarcinoma (44.1%; P<0.05). Furthermore, the incidence rates ofTYMSandTUBB3expression in the high-median differentiation tissue samples were significantly lower than those in the low differentiation tissue samples (P<0.05). When the correlation of gene expression and patient survival was analyzed, high expression ofERCC1, RRM1, TUBB3orTYMSwas found to be associated with poor prognosis (P<0.001, P=0.001, P=0.001 and P=0.001, respectively). ERCC1, RRM1, TUBB3 and TYMS are key factors involved in survival following surgical treatment in patients with NSCLC. The mRNA expression of these genes may have prognostic value for patients with NSCLC treated with platinum-based chemotherapy.
authors.affiliation: Department of Oncology, The General Hospital of People's Liberation Army, Beijing 100853, P.R. China.
authors.forename: Shengjie
authors.initials: S
authors.lastname: Sun
authors.affiliation: Department of Oncology, The General Hospital of People's Liberation Army, Beijing 100853, P.R. China.
authors.forename: Weiwei
authors.initials: W
authors.lastname: Shi
authors.affiliation: Department of Oncology, The General Hospital of People's Liberation Army, Beijing 100853, P.R. China.
authors.forename: Zhiyong
authors.initials: Z
authors.lastname: Wu
authors.affiliation: Department of Oncology, The General Hospital of People's Liberation Army, Beijing 100853, P.R. China.
authors.forename: Guoqing
authors.initials: G
authors.lastname: Zhang
authors.affiliation: Department of Oncology, The General Hospital of People's Liberation Army, Beijing 100853, P.R. China.
authors.forename: B O
authors.initials: BO
authors.lastname: Yang
authors.affiliation: Department of Oncology, The General Hospital of People's Liberation Army, Beijing 100853, P.R. China.
authors.forename: Shunchang
authors.initials: S
authors.lastname: Jiao
keywords: class III β-tubulin; excision repair cross-complementing 1; non-small cell lung cancer; ribonucleotide reductase subunit M1; thymidylate synthase